Carmot Therapeutics

United States
Berkeley, California, United States
5105279251 ★

Company profile

Carmot Therapeutics company profile

Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases. They employ their patented technology, chemotype evolution, to address the fundamental causes of disease and speed the discovery of disease-modifying therapies.

Business identity

Contact email
[email protected]
Phone number
5105279251
Operating status
Closed
Company type
For Profit
Employee range
00011-00050 employees
Revenue range
$10K+
Founded
2008-01-01

Headquarters

Headquarters
Berkeley, California, United States
Postal code
94158
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
8
Total equity funding
$384.8M
Last funding
Series E / $150M / 2023-05-25
Last equity funding
Series E / $150M
Investors
16
Lead investors
5
Founders
2
Articles
113
Closed on
2024-01-29
Exited on
2023-12-03

Founders and investors

Founders

Daniel A. ErlansonStig Hansen

Lead investors

Amgen VenturesDeep Track CapitalHorizons VenturesNational Science FoundationThe Column Group

Investors

5AM VenturesFranklin TempletonJanus Henderson InvestorsRA Capital ManagementTCG Crossover

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.